Cancer "immunity + targeting" combination therapy is coming! Clinical trials significantly prolong survival!
On January 20, Merck officially announced the results of a clinical trial of its PD-1 therapy and oral multi-receptor tyrosine kinase inhibitor (Coreda + Lewema) combined drug regimen. Overall survival, progression-free survival, and secondary endpoint overall response rate were all statistically significant and clinically significant.
Kreda + Lerema is an immune+targeted combination therapy that has been approved for the treatment of adult patients with advanced endometrial and advanced renal cell carcinoma. The results of the Phase 3 clinical trial revealed the treatment of 827 patients with endometrial cancer, and the median overall survival was extended from 11.4 months to 18.3 months and the risk of death was reduced by 38% compared with chemotherapy alone (doxorubicin or paclitaxel), the progression-free survival was extended from 3.8 months to 7.2 months, the risk of disease progression was reduced by 44%, and the overall response rate increased from 14.7% to 31.9%, which had significant improvement significance.
However, in terms of safety, the incidence of adverse events above the 3rd level of combination therapy was 88.9%, while the incidence of adverse events of chemotherapy was 72.7%.
Merck and its partners are currently conducting clinical trials of this combination therapy for more than 10 different types of tumors (including melanoma, liver cancer, non-small cell carcinoma, rectal cancer, stomach cancer, pancreatic cancer, etc.) in the hope of playing a stronger role in more types of tumors.
![There are two things in the world that can instantly close the distance between people: one is a smile, and the other is wine. Smiling is like wine – it can be intoxicating; life is like wine – having a smile is more mellow. @Headline number[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)